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Abstract
Background
Violence against women and girls (VAWG) is a human rights violation with social, economic,
and health consequences for survivors, perpetrators, and society. Robust evidence on economic, social, and health impact, plus the cost of delivery of VAWG prevention, is critical to
making the case for investment, particularly in low- and middle-income countries (LMICs)
where health sector resources are highly constrained. We report on the costs and health
impact of VAWG prevention in 6 countries.

Methods and findings
We conducted a trial-based cost-effectiveness analysis of VAWG prevention interventions
using primary data from 5 randomised controlled trials (RCTs) in sub-Saharan Africa and 1
in South Asia. We evaluated 2 school-based interventions aimed at adolescents (11 to 14
years old) and 2 workshop-based (small group or one to one) interventions, 1 communitybased intervention, and 1 combined small group and community-based programme all
aimed at adult men and women (18+ years old). All interventions were delivered between
2015 and 2018 and were compared to a do-nothing scenario, except for one of the schoolbased interventions (government-mandated programme) and for the combined intervention
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Cost-effectiveness of preventing violence against women and girls

(access to financial services in small groups). We computed the health burden from VAWG
with disability-adjusted life year (DALY). We estimated per capita DALYs averted using statistical models that reflect each trial’s design and any baseline imbalances. We report costeffectiveness as cost per DALY averted and characterise uncertainty in the estimates with
probabilistic sensitivity analysis (PSA) and cost-effectiveness acceptability curves
(CEACs), which show the probability of cost-effectiveness at different thresholds. We report
a subgroup analysis of the small group component of the combined intervention and no
other subgroup analysis. We also report an impact inventory to illustrate interventions’
socioeconomic impact beyond health. We use a 3% discount rate for investment costs and
a 1-year time horizon, assuming no effects post the intervention period. From a health sector
perspective, the cost per DALY averted varies between US$222 (2018), for an established
gender attitudes and harmful social norms change community-based intervention in Ghana,
to US$17,548 (2018) for a livelihoods intervention in South Africa. Taking a societal perspective and including wider economic impact improves the cost-effectiveness of some
interventions but reduces others. For example, interventions with positive economic
impacts, often those with explicit economic goals, offset implementation costs and achieve
more favourable cost-effectiveness ratios. Results are robust to sensitivity analyses. Our
DALYs include a subset of the health consequences of VAWG exposure; we assume no
mortality impact from any of the health consequences included in the DALYs calculations. In
both cases, we may be underestimating overall health impact. We also do not report on participants’ health costs.

Conclusions
We demonstrate that investment in established community-based VAWG prevention interventions can improve population health in LMICs, even within highly constrained health budgets. However, several VAWG prevention interventions require further modification to
achieve affordability and cost-effectiveness at scale. Broadening the range of social, health,
and economic outcomes captured in future cost-effectiveness assessments remains critical
to justifying the investment urgently required to prevent VAWG globally.

Author summary
Why was this study done?
• Governments are increasing funding for the elimination of violence against women and
girls (VAWG) by 2030 as part of sustainable development goal five (SDG5).
• The evidence to inform investment in this area is extremely limited, including from
low- and middle-income countries (LMICs), presenting a major obstacle to scaling up
violence against women prevention programming.
• Investigating the potential cost-effectiveness, health, and nonhealth impacts of prevention helps those working in violence against women prevention justify funding from the
health sector or other sectors interested in health improvement and women’s well-being.
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What did the researchers do and find?
• We report trial-based cost-effectiveness estimates for 6 interventions designed to prevent VAWG in 6 countries: Ghana, Kenya, Pakistan, Rwanda, South Africa, and
Zambia.
• We find that some interventions are likely to improve population health, even within
current health budgets in each country. Interventions are more likely to be cost-effective
at preventing women’s exposure to violence, rather than men’s perpetration. One-toone psychosocial support interventions for secondary prevention, while impactful, are
likely to be less cost-effective than primary prevention interventions in low-resource settings. Community- and school-based interventions are more likely to be cost-effective
from a health sector perspective.
• Considering all effects, interventions that improve participants’ livelihood skills, including their financial management skills, can be cost saving, while also reducing perpetration of violence from men, even if they do not reduce experience of violence among
women and girls in the short term.

What do these findings mean?
• The evidence suggests that established community-based interventions to prevent violence against women warrant consideration for immediate scale-up.
• However, to reach all populations in need with appropriate interventions, more investment is required to further develop and refine a range of prevention delivery models
that are impactful and contain costs, while developing the human resource expertise in
LMICs.
• Research funding is required to continue to enable rigorous impact, process, and economic evaluation of VAWG prevention that captures impact not only on violence exposure and perpetration, but also broader health and nonhealth impacts to ensure that the
strongest case for investment in the prevention of VAWG continues to be made
globally.

Introduction
Twenty-seven percent (uncertainty interval 23% to 31%) of women and girls aged 15 years or
older have experienced either physical or sexual intimate partner violence (IPV) or nonpartner
sexual violence globally [1]. Sustainable development goal five (SDG5) includes the elimination of all violence against women and girls (VAWG) by 2030. To support the achievement of
this goal in low- and middle-income countries (LMICs), official development assistance
(ODA) to end VAWG have been steadily increasing since 2016 [2]. A critical challenge is to
develop feasible and impactful prevention interventions that can be rapidly scaled up and sustained within the fiscal limits of LMIC governments and their development partners.
Funded by the Department for International Development (DFID) in the United Kingdom,
What Works to Prevent Violence is the first coordinated programme to conduct evaluation
across multiple countries using randomised controlled trials (RCTs) to assess both the impact
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and cost-effectiveness of VAWG prevention, including IPV, in LMICs. Evidence from What
Works [3] and other programmes suggests that preventing VAWG is feasible within tight programmatic timelines across a number of settings and platforms. Community-based interventions have shown promise [4,5] but, depending on the setting, only certain modes of delivery
may be effective [6]. School-based interventions have reduced corporal punishment [7] and
sexual assault against girls [8]: In Uganda, an RCT of an intervention that trained teachers to
avoid using corporal punishment found a reduction in teachers’ physical violence against students at 18-month follow-up (odds ratio 0.40, 95% CI (0.26 to 0.64), p < 0.0001) [7]. Likewise,
a cluster randomised matched pairs parallel trial of a behaviour-based intervention in Nairobi’s informal settlements similar to the one in our study reported a reduction in the risk difference of exposure to rape equal to 3.7% for schools in the intervention arm compared to those
in the control arm (95% CI (0.4% to 8.0%), p < 0.03) [8]. There is little evidence of the impact
on violence from curriculum-based interventions in schools [9]. However, a recent systematic
review found that 50% of adolescent dating violence programmes are effective in both highand middle-income countries [10].
For adults, workshop-based interventions have also been found to be highly effective
[11,12], particularly with specific subpopulations [12]. Workshop-based interventions have
shown promise in South Africa, among poor women eligible for access to microfinance services in peri-urban areas and among unemployed youth [13]. Some prevention interventions
that aim to improve broad economic well-being have demonstrated social and financial benefits for participants [14,15], but may not reduce exposure to IPV in the short run [16] and
exacerbate it at times [17]. Recent reviews of the IPV impact of economic interventions show
that in some cases, these interventions have no effect on IPV exposure [18], and, in some
cases, they may increase exposure to IPV, especially in terms of controlling behaviour and economic violence [17]. Finally, evidence from high-income settings suggests that VAWG prevention reduces the costs of police and criminal justice system, property damage, and clinical
health [19].
Despite the emerging evidence and high-level policy and public commitment to reducing
VAWG, funding for VAWG prevention remains scarce due to fiscal constraints on health,
education, and social service provision in LMICs. While the moral arguments for the prevention of VAWG are clear, evidence of the cost-effectiveness of VAWG prevention is often a prerequisite for significant increases in both domestic and development assistance funding.
However, to date, the evidence on cost-effectiveness of VAWG prevention is inconclusive,
with only 3 published cost-effectiveness studies of VAWG prevention available. The Intervention with Microfinance for AIDS and Gender Equity (IMAGE) offered women access to
microcredit services and life skills training/community mobilisation techniques [11]. IMAGE
is cost-effective against the 1xGDP threshold, but not against the health sector opportunity
cost threshold, but the intervention’s cost-effectiveness was low compared to other basic health
services in LMICs [20]. The SASA! community mobilisation intervention in Uganda reported
a 52% nonstatistically significant reduction in past year experience of physical IPV [4], but as
the study did not measure cost per disability-adjusted life year (DALY) averted, a standardised
measure of health outcomes, the intervention cannot be compared to investment in other
health interventions. SASA! reported a cost per year free from physical IPV of 2011 US$460
[21]. Unite for a Better Life (UBL), a combined workshop-based and community mobilisation
in Ethiopia, reported a cost per year free from physical and/or sexual IPV of 2015 US$194 at
the community level and 2015 US$2,726 for workshop participants [22]. Cost per year free
from IPV among UBL workshop participants are in line with IMAGE’s (2004 US$710) [23]; as
expected, community-level results are more favourable. However, they cannot be compared to
a cost-effectiveness threshold, as they are not expressed in terms of cost per DALY averted.
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Moreover, UBL’s estimate includes women only, men only, and couple’s interventions; SASA!
only refers to physical IPV and IMAGE reports on physical and/or sexual IPV of a womenonly intervention. Hence, we recommend caution when comparing the cost per year free from
IPV of these 2 interventions.
This paper presents the first standardised multicountry cost-effectiveness analysis, to our
knowledge, of interventions for the prevention of VAWG, employing methods commonly
used to justify investment in the health sector to assess costs, impact on burden of disease, and
cost-effectiveness [24]. It reports cost and cost-effectiveness in research settings and at scale,
using routine implementation scenarios derived in a previous paper [25]. We only report
observed direct effects, neither accounting for future direct effects nor for any indirect effects,
except for economic impact where this is available. Our estimates may thus underestimate
total intervention effect. However, direct effects are estimated within RCT settings, usually
characterised by higher effectiveness than routine implementation, potentially leading to an
overestimate of interventions’ direct impact on IPV prevention.
These findings will be of interest to researchers in the field of women’s empowerment and
violence prevention, to health and social policy makers and to implementers.

Methods
Overview
We report on the cost-effectiveness, health outcomes, and broader societal impact of 6 VAWG
prevention interventions in Ghana, Kenya, Pakistan, Rwanda, South Africa, and Zambia,
using a trial-based analysis. These 6 interventions were selected out of the 10 interventions
evaluated using RCTs for the What Works programme [3]. We selected the interventions that
were comparatively more established, as they had a higher likelihood of being considered for
adoption by policy makers if effective. We also selected them to be representative of delivery
platforms, target mechanisms, populations (adults, children; females and males), types of violence addressed, and geographies (Southern Africa and South Asia) available within this
group. Full details of all What Works studies are available on www.whatworks.co.za. It was not
our aim to compare one intervention across sites or to compare interventions’ cost-effectiveness across sites as each context is different. Rather, we synthesise findings on the cost-effectiveness of 6 cutting-edge implementation approaches in this field conducted as part of one
cohesive global programme of research.
We assessed cost-effectiveness using a standardised methodology we developed for VAWG
prevention and women’s empowerment interventions [26], by adapting state-of-the-art methods for economic evaluation in health and medicine [24,27,28] to the characteristics of behavioural interventions for the empowerment of women and girls and the prevention of VAWG:
This analysis meets the requirement of the reference case set out by the Second Panel on CostEffectiveness in Health and Medicine [29].
Our primary outcome measure is cost per DALY averted. We report cost per DALY averted
from both a provider and societal perspective, the former examining health sector costs and
outcomes only, and the latter including economic impact. A societal perspective is particularly
relevant for IPV prevention, because they are designed to impact recipients’ well-being beyond
health domains. We estimate health and IPV effects for the economic evaluation using the
same statistical models used to estimate interventions’ primary outcomes, as described in the
analysis section below and in Table 1. We also present an inventory of broad social (nonhealth)
impact [24]. We compared 6 VAWG prevention interventions to the status quo (control
groups) in each country, for trial populations over the time period of the trials (Table 1). We
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Table 1. Intervention descriptions—Research setting.
RRS

IMpower

RTP

Indashyikirwa

SSCF

VATU

Key study design characteristics and processes
Setting

Ghana (1), rural and
urban

Kenya, urban
(informal settlements)

Pakistan, urban

Rwanda, rural

South Africa, urban
(informal
settlements)

Zambia, urban (high
population density, lowincome compounds)

Location

Central region (2
districts)

Nairobi

Hyderabad (Sindh
Province)

Eastern, Northern,
Western provinces (7
districts)

Durban

Lusaka

Intervention sites

20 communities

52 schools

20 schools

14 sectors

17 sites

3 sites (123 families, 65 of
which also included 1
child in the study)

Target population Female (18 to 49 years)
and male (> = 18
years) adults who
usually live in the
household and have
lived in the
community for at least
1 year

Number of
potential
participants

Female children in
primary schools (11
to 14 years old (2), in
grades 5 to 8)

Families living in the
Not formally
Schools: single sex, Adults (18 to 49 years
study compounds in
employed female and
old) resident in the
public middle
Lusaka with at least 1
male adults (18 to 30)
community for at
schools in
female and 1 male adult
who normally reside
least 6 months;
Hyderabad with
(18+), and 1 child
in informal
married or living
playground or
with current partner
settlement cluster
between 8 and 17 years
indoor space that
old identified by the
can host 35 or more for at least 6 months,
mother as the most
not participating in
students for games.
affected by the violence.
the Indashyikirwa
Students: male and
The adult female must
female children in couples’ intervention
report (i) at least
primary schools
moderate violence within
(grades 6 to 8)
the family as defined
above; and (ii) hazardous
alcohol use by the adult
male in the household.
The latter must be
confirmed in the adult
male’s screening

73,759

24,055

15,968

141,733

677

246

Control group

Do nothing

Ministry of Education
mandated “life skills
course,” a one 2-hour
session on sexual and
reproductive health
and general life skills.
The session was
delivered by Ujamaa
facilitators in control
schools

Do nothing

VSLA only (VSLA
alone)

Do nothing

Safety checks

Time horizon

One year; 24 months
postbaseline

One year; 24 months
postbaseline

One year; 24
months postbaseline

One year; 24 months
postbaseline

One year; 24 months
postbaseline

One year; 12 months
postbaseline

July 2017 to September
2018

October 2017 to
September 2018

September to
October 2019

September 2017 to
December 2018

May 2018 to
September 2018

May 2017 to September
2018 (preliminary
interviews and financial
data: 2016)

Implementing
organisation(s)

Gender Studies and
Human Rights
Documentation
Centre

Ujamaa

RTP Pakistan

CARE Rwanda,
RWN and
RWAMREC

Project Empower

SHARPZ, Johns Hopkins
University

Approach

Addressing harmful
social norms on
gender and violence

Empowerment and
self-defense

Play based

Addressing harmful
social norms on
gender and violence

Gender
transformative and
livelihoods
strengthening

Psychotherapeutic
support

Cost data
collection

Intervention characteristics

(Continued )
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Table 1. (Continued)
RRS

IMpower

RTP

Indashyikirwa

SSCF

VATU

Community based

School based to
single-sex classes
after/during school
day

School based to
classes during
school

Community-based
and small groups

Small groups

One-to-one sessions

18 months

Six 2-hour sessions,
plus 2 booster
sessions, at 6 and 10
months, respectively

One-hundred
twenty 35-minute
sessions over 2
years, conducted
separately for boys
and girls

30 months

Twenty-one 3-hour
sessions, delivered
twice a week to single
sex groups of
approximately 20
over 4 to 6 months
per group

12 one-to-one weekly
sessions over a period of
12 weeks

2002

2009 to 2011 (3)

2008 to 2014

2013 to 2016

2011 to 2013

2010

January to December
2016

October 2009 to
March 2016

January 2015 to
February 2018

October 2015 to May
2016

December 2011 to
December 2015

September 2015 to May
2016

Implementation
phase

December 2016 to
December 2017

January to September
2016

November 2015 to
February 2018

September 2016 to
July 2018

January 2016 to
March 2017

June 2016 to December
2017

Primary violence
outcomes

Past year incidence of
IPV (perpetration of
physical and/or sexual
IPV for men and
experience for women)

Sexual assault within
past 12 months

Peer violence
victimisation in the
past 4 weeks; peer
violence
perpetration in the
past 4 weeks

IPV (sexual or
physical; experience
and perpetration)

Any past year
physical IPV
perpetration (men)
and experience
(women); any past
year sexual IPV
perpetration (men)
and experience
(women); past year
severe sexual and/or
physical IPV
perpetration (men)
and experience
(women); controlling
behaviours

Change in violence
against women as
measured by SVAWS

Other violence
outcomes

Institutional
assessment of violence
against women cases
[time frame: 3 years];
reported cases of
violence against
women IPV
(emotional violence;
economic violence);
nonpartner violence

Recurrent physical
and/or sexual IPV;
forced or coerced sex
with main partner;
physical IPV,
emotional IPV; help
seeking among
survivors of IPV;
children in household
witnessing IPV,
emotional violence

Corporal
punishment in the
past 4 weeks;
physical
punishment at
home in past 4
weeks

Other health
outcomes

Hazardous alcohol use, Alcohol and drug use;
drug use, depression, PTSD; depression and
abortion
anxiety at 24 months;
self-efficacy and wellbeing

Platform of
delivery

Number of
implementation
sessions or
duration

Year(s)
intervention
developed
Start-up phase

Outcomes

Depression

Recurrent physical
IPV (emotional
and/or sexual IPV;
violence; economic
forced or coerced sex violence); nonpartner
with main partner;
violence
physical IPV,
emotional IPV;
sources of
information on IPV
and number of times
heard; help seeking
among survivors of
IPV; economic abuse
with main partner;
children in
household witnessing
IPV; change in
strategies used to
address IPV
Hazardous alcohol
use

Change in child abuse as
measured by the Youth
Victimization Scale;
change in psychological
violence as measured by
Index of Psychological
Abuse

Hazardous alcohol
Change in alcohol abuse
use, drug use,
as measured by AUDIT;
depression, suicidal
Change in depression
ideation, life
symptoms as measured
circumstances, last
by the CES-D; Change in
sexual partner,
PTSD symptoms (adult)
transactional sex past as measured by the HTQ;
year, stress about lack Change in substance use
of work
as measured by ASSIST
(Continued )
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Table 1. (Continued)

Nonhealth
outcomes

Primary outcome
for the economic
evaluation

RRS

IMpower

RTP

Indashyikirwa

SSCF

VATU

Income, gender
attitudes

Gender norms

School attendance,
school performance,
early marriage,
gender attitudes

Income; gender
attitudes; support for
women working
outside the home

Earnings in past
month; gender
attitudes,
consumption and
savings, life
circumstances, shame
about lack of work,
mobilisation of
money in an
emergency, stealing
because of hunger in
past month

Change in belief about
gender norms as
measured by the GEMS

Incidence of peer
violence
victimisation in the
past 4 weeks as
measured with the
PVS

Past year incidence of Past year incidence of
IPV (perpetration of IPV (perpetration of
physical and/or sexual
physical and/or
IPV for men and
sexual IPV for men
and experience for
experience for
women) captured by women) captured by
WHO measures
WHO measures

Past year incidence of
IPV (perpetration of
physical and/or sexual
IPV for men and
experience for women)
captured by WHO
measures

Past year incidence of Past year incidence of
IPV (experience of
IPV (perpetration of
physical IPV for
physical and/or sexual
IPV for men and
female children)
captured by WHO
experience for women)
measures
captured by WHO
measures

Study-level statistical analysis for intervention effect estimates
Statistical model

Difference in
differences

Level of analysis

Generalised linear
mixed model for
change

Generalised linear
mixed model for
change

Generalised linear
mixed model for
change

Generalised linear
model first difference

Generalised linear mixed
model for change

Village summaries

Student

Student

Individual

Individual

Individual

Link function

N/A

Binary outcomes:
Logit (continuous
outcomes: Gaussian)

Binary outcomes:
Logit (continuous
outcomes:
Gaussian)

Binary outcomes:
Logit (continuous
outcomes: Gaussian)

Binary outcomes:
Logit (continuous
outcomes: Gaussian)

Binary outcomes: Logit
(continuous outcomes:
Gaussian)

Random effects
(level)

No

Yes (cohort, cluster,
individual)

Yes (school)

Yes (sector)

No

Yes (counsellor, couple)

Robust standard
errors

No

Yes

No

No

Yes, clustered at
settlement level

Yes

Difference in
differences

Adjusted change in
odds ratios
(differences)

Adjusted odds ratios
(differences) at 24
months

Adjusted change in
odds ratios
(differences)

Adjusted odds ratios
(differences) at 24
months

Adjusted change in odds
ratios (differences)

Effect estimate

ASSIST, Alcohol, Smoking, and Substance Involvement Screening Test; AUDIT, Alcohol Use Disorders Identification Test; CES-D, Center for Epidemiological Studies
Depression Scale; GEMS, Gender Equitable Men’s Scale; HTQ, Harvard Trauma Questionnaire; IPV, intimate partner violence; PTSD, post-traumatic stress disorder;
PVS, Peer Victimization Scale; RRS, Rural Response Systems; RTP, Right To Play; RWAMREC, Rwanda Men’s Resource Centre; RWN, Rwanda Women’s Network;
SSCF, Stepping Stones and Creating Futures; SVAWS, Severity of Violence Against Women Scale; VATU, Violence and Alcohol Treatment; VSLA, village savings and
loan association; WHO, World Health Organization.
https://doi.org/10.1371/journal.pmed.1003827.t001

then estimated potential cost-effectiveness should VAWG prevention be delivered to the entire
eligible population for each country, assuming impact can be maintained at scale.
We estimated the incremental cost of all interventions using primary data collected during
the trial period. We mapped the processes and costed the resources used in developing, adapting, setting up, and implementing the interventions; see Torres-Rueda and colleagues [25] for
more details. Health and other outcomes were estimated directly from the end line surveys for
all RCTs, with DALYs calculated using trial participants’ directly reported health outcomes.
We also report interventions’ impact on past year exposure and perpetration of violence, and a
cost per year free of violence. We do not include potential posttrial health benefits, conservatively assuming no sustained costs nor health, economic, or social impact.
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Study setting and interventions
Selected interventions employed 3 types of delivery platforms: classes within schools, community mobilisation, and one-on-one or small group workshops (including counselling) and
were delivered in urban (Kenya, Pakistan, South Africa, and Zambia) and rural settings
(Ghana and Rwanda). The interventions targeted different impact mechanisms defined using
theories of change: economic empowerment alongside a gender empowerment component
(South Africa and Rwanda); psychological empowerment (Kenya and Pakistan), including
self-defense (Kenya) and psychotherapeutic (Zambia); gender attitudes and behaviours (South
Africa, Ghana, Pakistan, and Rwanda), and social norms change (Ghana and Rwanda)
(Table 1). Published protocols [30] and impact evaluations [6,31–36] contain more details on
each intervention.
The interventions address the needs of different population groups experiencing violence
(Table 1). Interventions in Ghana, Rwanda, and South Africa targeted adult populations (18+);
for the Zambian intervention, we only report results for adults (18+) because the study was not
powered to report on children. The intervention in Kenya targeted 11- to 14 year-old schoolgoing girls, and the study was powered to detect the intervention’s effect on girls’ exposure to
sexual assault. The study collected data on boys as an exploratory outcome, but these data were
not available at the time of writing. The Right To Play (RTP) intervention in Pakistan sought
to reduce the perpetration and experience of peer-to-peer violence among 11- to 14-year-old
school-going children [30]. All but the Pakistani and Kenyan interventions measured sexual
and/or physical IPV among adults [5,6,16,31,32] as their primary outcome. All studies except
Violence and Alcohol Treatment (VATU, Zambia) used the World Health Organization
(WHO) IPV measure. VATU used WHO measure as a secondary outcome and the Conflict
Tactics Scale (CTS) as primary [31]. Comparator interventions (the status quo) (i.e., control
arm) were mainly “do nothing” except for Kenya and Rwanda (Table 1).

Outcomes
To estimate incremental DALYS averted by each intervention compared to the status quo, we
estimated the DALYs attributable to the health sequelae, i.e., health consequences, found for
each intervention using trial data (Table 2). Several studies identify a number of physical and
psychological health consequences of IPV. The link between the health sequelae we include
and IPV is well established [37]. See Fig A in S1 Appendix for a more detailed list. We also
report cost per year free of violence in the Appendix (Table G in S1 Appendix). This information can be useful for VAWG prevention programming. The outcomes for each RCT were
defined differently by each RCT research team so health sequelae measured varied by each
RCT (Table A in S1 Appendix). For community interventions, study participants were a randomly selected representative sample of the total population receiving the intervention
(Table 1). To arrive at cost per participant, we divide total costs by the number of recipients.
The health sequelae we included when estimating DALYs for the adult populations are the following: having a moderately high level of depression (Center for Epidemiological Studies
Depression Scale [CES-D] 20 �22), past year drug use, and hazardous alcohol use (The Alcohol Use Disorders Identification Test Consumption questions [AUDIT-C] �4 for males,
AUDIT-C �3 for females) (Table A in S1 Appendix). The sequelae were measured with the
same instruments across interventions targeting the adults, except the Rwandan RCT that
measured alcohol use (AUDIT-C) only. Pakistan measured depression among children using
the Child Depression Inventory II32 to identify cases of depression (CDI �65 points). The
Kenyan study measured anxiety and depression in children using the Beck Youth Depression
and Anxiety Inventories (BDI-Y and BAI-Y, respectively) (Table A in S1 Appendix). Cutoff
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thresholds were not publicly available for the Youth Self-Report (YSR), the measure of depression used for children in the Zambia intervention. Moreover, the study was not powered to
report the intervention’s impact on children, and they were not included in our DALY estimates. We measure peer violence in Pakistan with the Peer Victimization Scale (PVS) [38], the
study’s primary outcome. For all other interventions, we measure exposure to physical or sexual IPV using the WHO measure.

Cost estimation
We measured providers’ resource use and economic costs with a bottom-up microcosting
approach [26]. We identified the activities necessary to develop, adapt, set up, and implement
the interventions alongside the RCTs (research setting) by conducting semistructured interviews or direct observation, where possible, and reviewing financial documents, monitoring
and evaluations records, and other log books. We entered the data in standardised costing
workbooks [39] to estimate the cost per participant reached, using an intention-to-treat
approach. For more details on the estimation and analysis of providers’ costs, see Torres
Rueda and colleagues [25] and the S1 Appendix (p. 1–4).
We report costs for 2 settings: costs of “implementation in a research setting” and “implementation in a routine setting.” The costs of implementation in a research setting were the
costs measured in the trials, but excluded all direct costs related to research (e.g., monitoring
and evaluation activities only required for study purposes). The costs of implementation in a
routine setting were then estimated for 2 national scale-up scenarios, using assumptions about
the level of coverage and size of the organisations delivering interventions at scale. Details on
the process used to derive relevant assumptions are published elsewhere [25] (S1 Appendix,
p. 3–4).
We collected information on adult participants’ economic outcomes as part of the RCTs.
We used past year consumption as a proxy for disposable income to measure the economic
(productivity) impact of an intervention. Consumption is a preferable measure to report
income for productivity, given the low proportion on waged earners in LMICs [40] and a low
propensity to save in poor households [41]. We estimated the intervention’s incremental
impact on adult participants’ productivity compared to controls with the same statistical models used for the RCTs health outcomes. We then subtracted any estimated per capita productivity gain from the per capita cost of the intervention to obtain the net societal cost of the
intervention for the incremental cost-effectiveness ratio (ICER) from a societal perspective,
following current cost-effectiveness analysis guidelines [24].

Analysis
Effect estimates. We estimate impact using the statistical model used to generate the RCT
primary and secondary results, in line with previously published results, reporting estimates
for females only and for females and males jointly (all). For Ghana, impact is estimated using a
linear difference-in-differences model on village summaries [5]. Kenya, Pakistan, Rwanda, and
Zambia estimate the difference in differences (or ratio of risk ratios) using generalised mixed
models that reflect trial design and adjust for any baseline imbalances [6,31,32]. South Africa
estimates impact at 24 months adjusting only for each baseline outcome variable of interest
(first difference), having found no baseline imbalances in other predictors [36]. For Kenya, we
do not adjust for baseline scores of the outcome of interest because depression and anxiety
were only measured at end line.
We first report interventions’ impact on IPV and on the health outcomes used in our
DALY estimation from the RCTs. To compute the total number of IPV-free (or peer violence)
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years gained, we first estimated the adjusted difference in absolute risk of IPV (or peer violence) exposure or perpetration between intervention and control group; we then multiplied
the adjusted risk difference by the total number of participants randomised to the treatment
arm at baseline (equivalent to an intention-to-treat approach) to arrive at the total number of
IPV-free (or peer violence) years gained. To estimate incremental DALYs averted, we computed the adjusted risk difference in DALYs averted between intervention and control group.
Cost-effectiveness estimates. We assessed cost-effectiveness for females and males (all)
and for females only. All analyses were conducted in USD 2018 prices, and provider costs were
discounted using a rate of 3% (further details on exchange rates and other conversions can be
found in S1 Appendix, p. 2). DALYs were not discounted because we assume no effect beyond
the trial period. We assessed cost-effectiveness by estimating the probability that the incremental cost per DALY averted (or ICER) is cost-effective using 2 different thresholds to define
when an intervention is “declared” as cost-effective employed by Ministries of Health/public
funders. The first compares cost per DALY averted from a provider perspective to each country’s “opportunity cost” threshold [20]. Opportunity cost thresholds assess whether an intervention performs better than the least efficient in the health sector. As such, they measure
when funding a new intervention will improve population health if funded within current government health sector budgets. The second threshold is applied to the societal perspective
cost-effectiveness ratios. Here, the probability that each intervention is cost-effective the “societal” ICER is compared against each country’s per capita GDP in 2018. This provides an example of threshold from the perspective of a societal decision-maker who may consider funding
beyond the health sector. We also present cost-effectiveness acceptability curves (CEACs) for
those adopting different thresholds.
To account for the uncertainty in ICER estimates, we performed a probabilistic sensitivity
analysis (PSA) to generate 10,000 incremental cost and DALY pairs assuming gamma distributions on provider costs and normal distributions on DALYs and net costs. We parametrised
the distributions on health and economic outcomes using the within-trial estimates and the
distributions for provider costs with values of alpha and beta such that their product yielded
the mean cost per participant that emerged from our cost analysis [25]. We tested distributional fit with standard tests (Tables C and D in S1 Appendix, p. 8). We used the results of the
PSA to plot CEACs, which show the proportion of simulations that are cost-effective at the
two thresholds stated above.
We conducted several deterministic sensitivity and scenario analyses. First, we explored
how our results would be influenced if we replaced our direct measurement of health outcomes with an indirect measure of DALYs averted per IPV or peer victimisation case averted.
Prevention interventions act on health sequelae in different ways, not necessarily related to
IPV (e.g., a participant’s depression may also be due to other factors) and not all RCTs measured all possible health outcomes (Fig A and p. 6 in S1 Appendix). We therefore also estimated IPV-only DALYs using estimates of population health outcomes associated with
VAWG (used by the Institute of Health Metrics and Evaluation (IHME) to estimate the global
burden of disease) together with estimates of the incremental IPV cases averted by the intervention (S1 Appendix, p. 6–7 and 9–10).
Second, we estimated 2 scenarios to adjust the costs from the trial “implementation in a
research setting” to those for scaled up “implementation in a routine setting.” This was done
using several assumptions. Scenario 1 models the inputs/resources needed to achieve national
scale of the intervention trialled. Scenario 2 also modifies delivery processes as discussed in
consultations with implementers on how the intervention would likely be implemented at
scale (details on the cost analysis are provided in Torres-Rueda and colleagues [25] and S1
Appendix, p. 1–4).
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Third, we conducted a subpopulation analysis for Rwanda, where the intervention was
divided into phases targeting specific subpopulations. The gender transformative programme
in Rwanda was initially offered to village savings and loan associations (VSLAs) participants
(male–female couples) in small groups (VSLA-plus). Some of the couples were then trained in
community mobilisation using an approach derived from SASA! [4] to encourage shifts in
beliefs, attitudes, norms, and behaviours among members of their wider communities. The
complete intervention also included opinion leader training and community safe spaces for
women. We report a subpopulation analysis of cost-effectiveness on the recipients of the
VSLA-plus component, [32] because it was delivered through a distinct platform from the
community model (S1 Appendix, p. 11–12).
We did not explore further subgroup analysis by age group, because it is unlikely that
implementation would target only specific age groups and not others, as the interventions
were designed for the groups they were tested on. We conducted the analysis in Stata 15.1 [42].

Ethics approval and trials registrations
This study obtained ethics approval from the London School of Hygiene & Tropical Medicine
(LSHTM) Ethics Committee (#12204) and all local and research partners’ ethics committees:
the Noguchi Memorial Institute for Medical Research, University of Ghana (006/15-16), Kintampo Health Research Centre Institutional Ethics Review Committee IRB (#2017–15) and
South Africa MRC (EC031-9/2015) (Ghana); KEMRI Scientific and Ethics Review Unit
(KEMRI/RES/7/3/1) and Stanford IRB (#34706) (Kenya); Agha Khan University IRB (#20191544-4273) (Pakistan); Rwanda National Ethics Committee (#880/RNEC/2016) and South
Africa MRC (EC033-10/2015) (Rwanda); University of Zambia Bioethics Research Ethics
Committee (004-11-15) and Johns Hopkins University IRB (#6534) (Zambia); and University
of Kwa-Zulu Natal, Biomedical Research Ethics Committee (BFC043/15) and South African
MRC (EC006-2/2015) (South Africa). Trials’ registrations on ClinicalTrials.gov are the following: Ghana: NCT03237585; Kenya: NCT02771132; Pakistan: NCT03448523; Rwanda:
NCT03477877; South Africa: NCT03022370; and Zambia: NCT02790827.
Role of the funding source. The study sponsor, U.K. Aid from the U.K. Government,
played no part in study design; in the collection, analysis, and interpretation of data; in the
writing of the report; and in the decision to submit the paper for publication.

Results
Table 2 presents interventions’ impact on the violence and health outcomes we use in the costeffectiveness analysis (for goodness of fit tests, see Table H in S1 Appendix). The South African
intervention reduced VAWG, especially in terms of men’s perpetration. It also reduced
depression, although this is imprecisely estimated and did not have an impact on alcohol consumption. The intervention in Ghana achieved moderate impact on VAWG and alcohol consumption and reduced depression (Table 2). The Zambia couples’ psychological intervention
achieved substantial reduction of hazardous alcohol use by males, in addition to reducing
women’s exposure to and men’s perpetration of VAWG (Table 2). In Rwanda, the community
intervention had no impact on VAWG or alcohol misuse; the couples’ intervention reduced
VAWG and depression, but records no impact on alcohol misuse (Table E in S1 Appendix).
The Kenyan intervention delivered health benefits in the related domains of depression and
anxiety for adolescents, but no effect on physical violence from an intimate partner (Table 2).
In Pakistan, the intervention achieved large reductions in violence and depression, although
both are imprecisely estimated. Each study reported separately on all predeclared primary and
secondary outcomes [5,6,31,32,34–36].
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Table 2. Outcomes at 24 months by intervention arm (24 months postbaseline, unless otherwise specified)^.
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For the RRS trial, analysis is at the village summary level. We also report number of study participants for consistency with other studies.
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Futures; VATU, Violence and Alcohol Treatment.

DMC, Data Monitoring Committee; IPV, intimate partner violence; IRB, Institutional Review Board; RRS, Rural Response Systems; RTP, Right To Play; SSCF, Stepping Stones and Creating

Measured at 12 months postbaseline. The DMC at Johns Hopkins University’s IRB recommended the study be interrupted and the intervention delivered to study participants in the control arm,
following evidence of effectiveness at 12 months.

��

the adjusted odds ratio.

No anxiety result is reported for the analysis on both men and women, because in no study was anxiety measured at both baseline and end line for both groups.
�
The Indashyikirwa community study employed 2 repeated cross-section surveys of random household samples (6). We report the average number of unique individuals in each survey round for

§

‡

^Sample sizes reported in this table refer to highest number of respondents across the analyses reported for each intervention.

VATU�

SSCF

Table 2. (Continued)
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Table 3 presents the summary costs for each intervention. Provider costs per participant
range from $3.95 for the community intervention in Ghana to $1,324 for one-on-one counselling in Zambia in the implementation in a research setting.
Table 3. Annuitised intervention costs± (2018 US$).
RRS

IMpower±§

RTP§

Indashyikirwa

SSCF

VATU±

Ghana

Kenya

Pakistan

Rwanda

South Africa

Zambia

Provider perspective
Research setting
Total incremental cost
Potential recipients at baseline
Incremental cost per capita

$291,215

$130,065

$355,722

$2,905,087

$216,237

73,759

11,444

15,968

141,733

677

$325,626
246

$4

$11

$22

$20

$319

$1,324

$33,736,232

$38,807,824

$175,185,264

$57,219,812

$108,667,408

��

12,210,626

1,832,742

4,057,000

4,563,077

490,350

��

$3

$21

$43

$13

$222

��

$37,729,012

$38,807,824

$175,564,656

$60,143,504

$118,814,576

��

12,210,626

1,832,742

4,057,000

4,563,077

490,350

��

$3

$21

$43

$13

$242

��

Scale-up scenario 1
Total incremental cost
Potential number of participants
Incremental cost per capita
Scale-up scenario 2
Total incremental cost
Potential number of participants
Incremental cost per capita

Societal perspective
Research setting
−$26,294,262

$130,065

$355,722

$2,905,440

$1,224,630

��

Potential recipients at baseline

73,759

11,444

15,968

141,733

677

��

Incremental cost per capita

−$356

$11

$22

$20

$1,809

��

−$4,367,426,048

$38,807,824

$175,185,264

$57,231,172

$839,044,672

��

12,210,626

1,832,742

4,057,000

4,563,077

490,350

��

−$358

$21

$43

$13

$1,711

��

−$4,363,433,472

$38,807,824

$175,564,656

$60,154,864

$849,191,872

��

12,210,626

1,832,742

4,057,000

4,563,077

490,350

��

−$357

$21

$43

$13

$1,732

��

Total incremental cost

Scale-up scenario 1
Total incremental cost
Potential number of participants
Incremental cost per capita
Scale-up scenario 2
Total incremental cost
Potential number of participants
Incremental cost per capita

Note: Table 3 reports annuitised costs for each intervention, i.e., equivalent annual costs obtained by spreading initial investment over the course of its useful life using
standard tables (see Ferrari and colleagues [26] for methodological details). The provider perspective includes costs of adaptation and delivery only. Societal perspective
also includes interventions’ economic impact for participants, where this is available (South Africa, Rwanda, and Ghana). Research setting report costs incurred during
trial period. Scale-up scenarios report resource requirements for implementation at national scale, accounting for fixed and variable costs and intervention
modifications. Scenario 1 includes changes in inputs (e.g., employing schools’ teachers to deliver the intervention, instead of specialised trainers) and modifications (e.g.,
reductions in number of sessions or training time for trainers); scenario 2 only includes changes in inputs, with no modification to intervention delivery model. Total
incremental cost is the total annuitised cost of delivering the intervention at scale. Potential number of participants in the research setting is the number of participants
enrolled in the intervention at baseline for group-based interventions and the number of pupils or community members for school-based or community-based
interventions, respectively; in the scale-up scenarios, it is the number of individuals in the target population at the national level. Incremental cost per capita is the ratio
of total incremental costs over the potential number of participants in each scenario. For more details, see Torres-Rueda and colleagues [25].
±
Cost per participant is computed over total participants except for VATU and IMpower. For VATU, only costs and participant numbers for adults are considered,
because the children were excluded from the main study. For IMpower, only girls are considered, because the boys were excluded from the main study. Total
incremental costs of delivery to female participants are computed pro rata: Intervention delivery processes did not change by gender of participants. Incremental costs
presented here from IMpower are net of the cost of delivering a government mandated session in control schools. These calculations imply that the incremental cost per
capita for females differs slightly from per capita costs for the entire sample presented in the costing paper. For details on the cost analysis, see Torres-Rueda and
colleagues [25].
��
Data not provided by study.
§

These interventions are offered to children, and no economic impact is measured on this population, given the 12-month time frame of the study. This explains why,

for these interventions, provider and societal costs are the same.
RRS, Rural Response Systems; RTP, Right To Play; SSCF, Stepping Stones and Creating Futures; VATU, Violence and Alcohol Treatment.
https://doi.org/10.1371/journal.pmed.1003827.t003
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From a societal perspective, per participant results range from a net saving of $356 in
Ghana to a net cost of $1,809 in South Africa (Table 4). Table 4 presents the incremental cost
per DALY averted for men and women and women only respectively. Figs 1 and 2 present
CEACs showing the probability of the intervention being cost-effective under different decision rules (see Figs G and H in S1 Appendix for the corresponding bootstrapped cost and
effect pairs).
From a health sector perspective, the Ghanaian intervention has a 52% probability of being
cost-effective for men and women jointly and a 95% probability of being cost-effective for
women only compared to Ghana’s opportunity cost threshold (Table 4, Fig 1). The intervention averts 1 DALY for US$52 for female participants and for US$360 when the health impact
on men is also considered. The intervention has an 80% probability of cost-effectiveness when
considering a societal perspective for both men and women. For women only, the Ghana intervention records a 95% probability of cost-effectiveness from a health sector perspective and a
62% probability from a societal perspective. The Kenyan intervention (IMpower) has 30%
probability of being cost-effective, improving the mental health of school girls generally
(Table 4, Fig 1). The intervention in Pakistan has a 0% probability of being cost-effective from
a health sector perspective, but from a societal perspective, the intervention is 38% likely to be
cost-effective. The South African intervention has no impact on DALYs for women but provides an economic benefit. When men are included, the economic impact on participants is
lower than among controls, and DALYs averted are marginally larger. The intervention has a
17% probability of being cost-effective from a societal perspective. None of the analyses for the
intervention in Zambia (VATU) found the intervention to be cost-effective from a provider
perspective.
In scale-up scenarios, patterns of cost-effectiveness remain similar compared to the
research setting apart from VATU, for which we do not have scale-up data (Figs 3–6). In
Ghana, probability of cost-effectiveness is unchanged between research setting and scale-up
from a health sector perspective (95% for females; 52% for females and males) and from a societal perspective (females: 63%; females and males: 81%). In South Africa, too, probabilities of
cost-effectiveness increase markedly for females from the societal perspective, compared to the
health sector perspective (from 1% to 90% in scenario 1; from 1% to 89% in scenario 2). Patterns remain unchanged for Kenya, and Pakistan is not cost-effective in any of the scale-up
scenarios. None of the analyses for the full intervention in Rwanda found it to be cost-effective,
although both scale-up scenarios record a 6 to 7 percentage point increase in probability for
females from a societal perspective (from 0% in research setting to 6% to 7% at scale-up).
For all interventions, our sensitivity analyses around IPV-attributable DALYs (Figs B–D in
S1 Appendix) suggest that the interventions are less cost-effective from a health sector perspective than when using DALYs directly computed from health sequelae. The subpopulation analysis for the Rwanda Couples intervention finds a 53% and 100% probability of being costeffective for a health sector and societal perspective respectively (Figs E and F in S1 Appendix).
Table G in S1 Appendix reports cost per year free from violence for all interventions. The
impact inventories report on outcomes relevant to the labour and financial, social services and
protection, education, and legal sectors of the economy for each intervention (Figs I–K in S1
Appendix).

Discussion
We present here the first substantial multicountry body of evidence on the impact and costeffectiveness of preventing VAWG, to our knowledge. We assess whether interventions are
affordable, given their respective countries’ health budgets. We do this by establishing cost-
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Table 4. Cost-effectiveness� .
IMpower±§

RRS
Ghana
Estimate

Kenya

95% CIs

Estimate

RTP§

Indashyikirwa

Pakistan

95% CIs

Estimate

Rwanda

95% CIs

Estimate

VATU±

SSCF
South Africa

95% CIs

Estimate

95% CIs

Zambia
Estimate

95% CIs

All
Provider perspective
IPV-free personyears gained

2,431.24

(−839.56
to 5,702.03)

Peer victimisation
free person-years
gained

6,373.59

(−13,338.86
to 26,053.19)

−21,251.17

(−51,976.21
to 9,473.87)

31.42

(−0.34
to 63.17)

264.27

(59.05
to 469.49)

809.59

(−14,027.17
to 15,646.34)

152.95

(−372.56
to 678.46)

−330.11

(−1,508.45
to 848.22)

11.86

(−14.20
to 37.91)

34.50

(6.43
to 62.58)

DALYs averted per
1,000 participants

10.98

(−190.18
to 212.13)

9.58

(−23.33
to 42.49)

−2.33

(−10.64
to 5.98)

17.51

(−20.97
to 56.00)

140.25

(26.13
to 254.37)

DALYs averted per
participant

0.01

(−0.19
to 0.21)

0.01

(−0.02
to 0.04)

0.00

(−0.01
to 0.01)

0.02

(−0.02
to 0.06)

0.14

(0.03
to 0.25)

Provider cost per
capita

$3.9

$22

$20

$319

$1,324

Incremental cost
per DALY averted

$360

$2,326

−$8,800

$18,239

$9,438

Opportunity cost
threshold

$497

$177

$281

$3,266

$546

Probability costeffective

52%

0%

0%

0%

0%

Economic impact
per capita

$360

DALYs averted
during the study
period

Societal perspective

Net cost
Incremental cost
per DALY averted
GDP per capita
threshold
Probability costeffective

−$.0025

(−369.81
to 1,090.69)

(−0.00
to −0.00)

−$1,490

(−5,013.90
to 2,034.89)

��

��

−$356

$22

$20

$1,809

��

��

−$32,479

$2,326

−$8,801

$103,292

��

��

$2,202

$1,482

$773

$6,374

��

��

80%

38%

0%

17%

��

��

Females only
Provider perspective
IPV-free personyears gained

1,162.72

(−564.00
to 2,889.45)

−97.28

(−502.21
to 307.66)

Peer victimisation
free person-years
gained

6,193.62

(−3,416.82
to 15,792.75)

−15,468.78

(−38,359.63
to 7,422.06)

5.79

(−21.01
to 32.58)

20.28

(9.00
to 31.57)

2,724.71

(−456.48
to 5,905.90)

89.96

(−293.14
to 473.06)

−5.50

(−359.40
to 348.40)

562.40

(−199.52
to 1,324.32)

−1.38

(−21.43
to 18.68)

21.41

(7.70
to 35.13)

DALYs averted per
1,000 participants

76.14

(−12.76
to 165.04)

7.86

(−25.62
to 41.34)

−0.66

(−43.29
to 41.97)

7.80

(−2.77
to 18.37)

−4.06

(−63.21
to 55.09)

174.09

(62.59
to 285.59)

DALYs averted per
participant

0.08

(−0.01
to 0.17)

0.01

(−0.03
to 0.04)

−0.00

(−0.04
to 0.04)

0.01

(−0.00
to 0.02)

−0.00

(−0.06
to 0.06)

0.17

(0.06
to 0.29)

Provider cost per
capita

$3.9

$11

$22

$20

$319

$1,324

Incremental cost
per DALY averted

$52

$1,446

−$33,614

$2,629

−$78,710

$7,603

Opportunity cost
threshold

$497

$656

$177

$281

$3,266

$546

Probability costeffective

95%

30%

0%

0%

0%

0%

Economic impact
per capita

−$83

DALYs averted
during the study
period

Societal perspective
(−520.78
to 354.46)

−$.0054

(−0.01
to −0.00)

$615

(188.25
to 1,041.14)

��

��

(Continued )
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Table 4. (Continued)

Estimate
Net cost

RRS

IMpower±§

RTP§

Indashyikirwa

SSCF

VATU±

Ghana

Kenya

Pakistan

Rwanda

South Africa

Zambia

95% CIs

Estimate

$87

$11

95% CIs

Estimate

95% CIs

$22

Estimate
$21

95% CIs

Estimate

Estimate

95% CIs

−$295

95% CIs

��

��
��

Incremental cost
per DALY averted

$1,144

$1,446

−$33,614

$2,630

$72,767

��

GDP per capita
threshold

$2,202

$1,711

$1,482

$773

$6,374

��

��

62%

52%

24%

0%

82%

��

��

Probability costeffective

Note: Table 4 reports results for all intervention participants (females and males) and for females only. Intervention effects are reported in natural units, IPV or peer
victimisation, and in DALYs averted. We also report DALYs averted during the study period to illustrate total health impact, according to available data. DALYs averted
per 1,000 participants are a commonly used standardised statistic. Provider costs are the costs of delivering the intervention only. Societal costs include the economic
impact interventions had on participants (not applicable to IMpower and RTP, which targeted children or early adolescents in schools). The opportunity cost threshold
is the cost per DALY of the least cost-effective intervention offered by the healthcare system of each country or the system’s marginal productivity. The 1xGDP per
capita threshold reflects WHO recommendations to determine cost-effectiveness. Probability cost-effective is the likelihood the intervention is cost-effective at the
designated threshold. This likelihood is computed using a PSA, where costs and effects are made to vary simultaneously to test the robustness of the reported ICER.
�

Intention-to-treat estimates: Totals are calculated with reference to all participants enrolled at baseline.

��
§

Data not provided by study.
See cost-effectiveness plane (Fig G in S1 Appendix).

DALY, disability-adjusted life year; GDP, gross domestic product; ICER, incremental cost-effectiveness ratio; IPV, intimate partner violence; PSA, probabilistic
sensitivity analysis; RRS, Rural Response Systems; SSCF, Stepping Stones and Creating Futures; VATU, Violence and Alcohol Treatment.
https://doi.org/10.1371/journal.pmed.1003827.t004

effectiveness of each intervention against an opportunity cost threshold based on econometric
estimates of actual health expenditure by each country’s health budget holders [20]. Comparing our cost per DALY averted estimates to these opportunity cost thresholds determines
whether each intervention should be afforded within its country’s existing health budget by
only finding an intervention cost-effective if it maximises population health within the
observed budget. We find that nearly all the interventions evaluated demonstrate a positive
impact on health and economic well-being (and other outcomes). For a limited number of prevention interventions, the evidence suggested that funding should be provided by the health
sector in LMICs. For others, the case is more challenging, because the probability of cost-effectiveness remains below 50% in all scenarios. However, a health sector perspective is the narrowest of frames for justifying investment in violence prevention and preventing human rights
violations. In this context, our findings suggest further investment in prevention intervention
design, and exploring platforms for broader cofunding from other sectors. Specifically, we find
that the probability that interventions are cost-effective for female beneficiaries increases for
most interventions when the societal perspective is considered, supporting a cross-sectoral
approach to VAWG prevention with a focus on women.
In terms of impact, interventions showed the strongest results in the areas for which they
were primarily designed and this design choice fundamentally impacts their potential costeffectiveness. The South African intervention, which focused on improving participants’ livelihood strategies, records the largest economic impact among female beneficiaries, in addition
to reducing men’s perpetration, but may need a more direct emphasis on VAWG to reduce
women’s exposure (Table 2). In Ghana, the larger economic benefits among male compared to
female beneficiaries exposure (Table 4) may reflect the societal gendered economic patterns.
More research is needed to confirm that this is an intervention effect, given that the intervention has no direct economic component. The intervention in Ghana was well established,
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Fig 1. Research setting, provider perspective. CEACs illustrating the probability that the intervention is effective for a range of thresholds. Dashed
vertical line: country-specific opportunity cost threshold; dashed horizontal line: probability that the intervention is cost-effective at the countryspecific threshold, given the cost per DALY averted by the intervention. CEAC, cost-effectiveness acceptability curve; DALY, disability-adjusted life
year; VATU, Violence and Alcohol Treatment.
https://doi.org/10.1371/journal.pmed.1003827.g001
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Fig 2. Research setting, societal perspective. CEACs illustrating the probability that the intervention is effective for a range of thresholds. Dashed
vertical line: country-specific opportunity cost threshold; dashed horizontal line: probability that the intervention is cost-effective at the countryspecific threshold, given the cost per DALY averted by the intervention. CEAC, cost-effectiveness acceptability curve; DALY, disability-adjusted life
year; VATU, Violence and Alcohol Treatment.
https://doi.org/10.1371/journal.pmed.1003827.g002
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Fig 3. Scale-up scenario 1, provider perspective. CEACs illustrating the probability that the intervention is effective for a range of thresholds.
Dashed vertical line: country-specific opportunity cost threshold; dashed horizontal line: probability that the intervention is cost-effective at the
country-specific threshold, given the cost per DALY averted by the intervention. CEAC, cost-effectiveness acceptability curve; DALY, disabilityadjusted life year.
https://doi.org/10.1371/journal.pmed.1003827.g003
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Fig 4. Scale-up scenario 1, societal perspective. CEACs illustrating the probability that the intervention is effective for a range of thresholds. Dashed
vertical line: country-specific opportunity cost threshold; dashed horizontal line: probability that the intervention is cost-effective at the country-specific
threshold, given the cost per DALY averted by the intervention. CEAC, cost-effectiveness acceptability curve; DALY, disability-adjusted life year.
https://doi.org/10.1371/journal.pmed.1003827.g004

PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003827 March 24, 2022

22 / 31

PLOS MEDICINE

Cost-effectiveness of preventing violence against women and girls

Fig 5. Scale-up scenario 2, provider perspective. CEACs illustrating the probability that the intervention is effective for a range of thresholds.
Dashed vertical line: country-specific opportunity cost threshold; dashed horizontal line: probability that the intervention is cost-effective at the
country-specific threshold, given the cost per DALY averted by the intervention. DALY, disability-adjusted life year.
https://doi.org/10.1371/journal.pmed.1003827.g005
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Fig 6. Scale-up scenario 2, societal perspective. CEACs illustrating the probability that the intervention is effective for a range of thresholds.
Dashed vertical line: country-specific opportunity cost threshold; dashed horizontal line: probability that the intervention is cost-effective at the
country-specific threshold, given the cost per DALY averted by the intervention. DALY, disability-adjusted life year.
https://doi.org/10.1371/journal.pmed.1003827.g006
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focused on VAWG, low cost, and embedded in communities; it achieved moderate impact on
VAWG [5] and DALYs averted. The Indashyikirwa Couple’s (Rwanda) (Table E in S1 Appendix) and VATU (Zambia) couples’ interventions are the 2 interventions that achieved a sizeable and statistically significant reduction in VAWG exposure and perpetration. The direct
focus on VAWG in Rwanda’s VSLA+ component may in part explain the cost-effective
approach to violence prevention. While the results are less clear, it should be noted that the
cost-effectiveness of the VATU intervention is in line with other mental health interventions
in sub-Saharan Africa [43]. One way of improving this outcome and help improve the costeffectiveness of mental health services overall may be to further integrate mental health services, training, or support with other health services and other VAWG prevention platforms
or interventions. The Kenyan intervention, focused on self-defense, delivered health benefits,
but showed no effect on rape, the main study outcome (not reported here), nor on physical
violence from an intimate partner (Table 2). However, this is an area with substantial measurement challenges, such as girls reporting having been raped but not having had sexual intercourse and the fact that there were fewer field staff at the third cohort interview than
previously assisting with this self-completed questionnaire. Inconsistent reports of having had
sex have been discussed by other authors from Kenya [44], and, hence, these results may be
less conclusive than other results presented here.
When improving the design of less cost-effective interventions, implementers need to think
about how delivery platforms or population characteristics may impact cost-effectiveness.
Some populations may simply be more expensive to reach, and, here, cost-effectiveness needs
to be traded off with equity considerations. For example, delivering interventions through
schools has the advantage of reducing costs of reaching children. However, it limits prevention
to school attendees, compared to a community intervention that may reach more vulnerable
youth at a lower cost per participant. Likewise, microfinance-plus interventions may be costeffective, but only reach actual microfinance clients, who often account for 10% to 36% of eligible microfinance clients in a village [45,46].
Our findings also suggest that long-established interventions may have performed better in
terms of cost-effectiveness thanks to very low costs, even in the face of considerable uncertainty in impact. Newly introduced community-based interventions, although potentially costeffective, need time to allow for local adaptation if they are to achieve impact at the population
level. Two years of implementation was sufficient for established community-based interventions that have been refined over time, such as the intervention in Ghana, but the experience
of Rwanda suggests that it may take 5 to 7 years to design, adapt, and introduce new prevention interventions [47].
Comparisons with the cost-effectiveness of similar interventions are limited, because of the
dearth of evidence. The only direct comparison between Stepping Stones and Creating Futures
(SSCF) and IMAGE [23] shows that the IMAGE intervention is more cost-effective from a
provider perspective. However, community and school-based What Works interventions tend
to compare favourably in terms of cost per year free from violence compared to previous interventions (Table G in S1 Appendix).
We find that accounting for economic impact alone can have substantial impact on intervention cost-effectiveness. Interventions with immediate economic impacts, but no VAWG
reduction, may look less favourable in the short term, but may provide more sustained benefits
if well designed and supported in the longer term. We therefore encourage practitioners to
think carefully through the economic implications of their interventions for beneficiaries not
only on account of the existing evidence of the links between economic outcomes and IPV,
but also of the implications of economic outcomes for interventions’ cost-effectiveness.
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Likewise, where effective, interventions with adolescents may intuitively produce sustained
behaviour change over many years.
We report a substantial variation in cost per participant of the different modes of VAWG
prevention [25]. The costs of VAWG prevention are largely driven by the intensity of contact
with participants and the types of human resource capacity required. While we found that
one-to-one contact with well-trained counsellors can result in substantial health improvement
in individuals, when compared to community focused or group interventions, this model was
costlier. Future work should explore whether integrating VAWG support (and prevention) in
general mental health services reduces costs at scale. School-based interventions, even if with a
health benefit, are unlikely to be funded by the health sector, and further attention needs to be
paid to models of cofinancing their costs within the education sector. This may also require
demonstrating improvements in educational outcomes. Community interventions can be
delivered at relatively low cost, and livelihood interventions, while costly to providers, can be
justified based on their overall societal cost savings. For all interventions, we need better
understanding of how costs may change at scale.
Results from our sensitivity analyses do not alter our general conclusions (see also S1
Appendix 1, p. 9–10). However, our study has several limitations. First, economic impact data
from Zambia were unavailable, and no economic impact data or reliable educational data were
collected for children. Second, we did not have the resources to collect data on study participants’ utilisation of health and social services. Third, some of our cost data could only be collected retrospectively [25]. Fourth, where men are committing perpetration outside of the
female study population, we may be underestimating overall health impact.
Our DALY estimation has 5 main limitations. First, we assume no health effects beyond the
trial period, because there are no estimates of long-term effects of VAWG prevention in the literature, making the modelling of such effects unreliable. Second, our effectiveness data were
obtained from RCTs and may be an upper bound estimate of intervention efficacy, compared
to real-world effectiveness in a nonresearch setting. However, it is also conceivable that the full
impact of interventions that seek to change deep-seated gender norms and behaviours accrues
over a time frame longer than 2 years, in which case our estimates could be lower bound estimates. Future studies should investigate the medium and long-term effects of IPV prevention
interventions. Third, we assumed no mortality impact from any of the conditions included in
the DALY measure. This is consistent with burden of disease estimations, but contradicts
other findings [48], and may bias our estimates downward. Fourth, we could only compute
binary indicators of cases for the health conditions included in the DALY. Distinguishing
between severe, moderate, or mild conditions would allow the application of more accurate
disability weights and reduce measurement bias. Fifth, our DALYs included only 2 to 3 of the
16 known potential health consequences of IPV exposure (Fig A in S1 Appendix), underestimating interventions’ health impact. Specifically, although several studies measured post-traumatic stress disorder (PTSD), there is no disability weight for PTSD hence our DALY
estimates exclude this potentially important health impact.
When interpreting our findings, it is important to note that this was not a single study
across multiple sites, and each RCT measured different sets of outcomes; it is therefore not
appropriate to directly compare across the RCTs. Future research should compare the incremental cost-effectiveness of all approaches comparatively for single populations. To enable
comparisons going forward, there is an urgent need for further standardisation of outcomes
measurement in the VAWG prevention field. Identification and consistent measurement of
health outcomes to be used to generate DALYs will allow for comparable and exhaustive estimates of health impact. Moreover, capturing the full range of impact in VAWG prevention
RCTs, including economic and social impact, can also be used to value interventions for other
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sectors and would further strengthen any case for investment in VAWG prevention [49].
Finally, while these findings add to the emerging evidence on the cost-effectiveness of VAWG
prevention, they should not be generalised beyond the populations targeted by the interventions. Further research on the context-specific drivers of both cost and impact across settings
is required, with both cost and impact monitored as part of implementation.

Conclusions
Preventing VAWG is a moral imperative. However, there is also an urgent need to demonstrate both its impact and cost-effectiveness given that competition for health and other funding is intense. Our study provides a major body of evidence on the cost-effectiveness of
VAWG prevention in LMICs. We provide robust findings on the cost-effectiveness of different
VAWG prevention interventions, highlighting the need for further intervention development
and research into new interventions. Findings suggest that investment in VAWG can improve
population health even in low-resource settings and even when only observed impact on IPV,
rather than lifetime projections, is considered. Overall, interventions are more likely to be
cost-effective for women and girls, although it should be borne in mind that these effects are
likely a combination of direct effects on females and indirect effects through men’s participation. The policy implications of our findings are that IPV prevention is likely a good investment from a health sector perspective and is also likely to improve populations’ overall wellbeing from a societal perspective. The valuation of the full range of outcomes of these interventions is a priority for policy and research to obtain a comprehensive picture of the cost-effectiveness of IPV prevention. Our findings present a major step forward towards this aim and in
justifying the scaled up and sustained response needed to meet SDG5, to more effectively
address VAWG globally.
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